Cipla Lines Up Advair But Costs Will Flatten High-Value Launches
Higher R&D Costs And Market-Driven Inflation Expected In 2022/23
A generic version of Advair is high on Cipla’s plans for its current financial year ending in March 2023. Management discussed the high-value respiratory asset and the company’s further prospects during the Indian firm’s annual earnings call, which included the company passing $1bn in sales for its domestic branded prescription business.
